Literature DB >> 17393318

MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism.

Youhei Horikawa1, Michiro Otaka, Koga Komatsu, Mario Jin, Masaru Odashima, Isao Wada, Tamotsu Matsuhashi, Reina Ohba, Jinko Oyake, Natsumi Hatakeyama, Raymond N Dubois, Sumio Watanabe.   

Abstract

Resistance to chemotherapeutic agents is one of the distinct features of cancer cells. We evaluate the role of activated MEK-ERK signaling in Camptotecin/irinotecan (CPT-11)-induced cell death using constitutively activated MEK1-transfected normal rat intestinal epithelial cells (IEC-caMEK cells). A CPT-11-induced inhibitory concentration of 50% was determined by WST assay. Apoptosis was evaluated by DNA staining and fragmented DNA analysis. Protein expressions were analyzed by western blotting. We also examined the role of cyclooxygenase-2 in the cell systems. IEC-caMEK cells possessed survival advantages compared to control cells. Apoptosis was remarkably suppressed in IEC-caMEK cells. Western blot analysis revealed increased expression of Bcl-2, Bcl-xL, Mcl-1, and COX-2 and decreased expression of Bak in IEC-caMEK cells. The COX-2 selective inhibitor ameliorated the antiapoptotic nature of IEC-caMEK cells. MEK activation suppressed CPT-11-induced apoptosis in IEC-caMEK cells via a COX-2- dependent mechanism. Therefore, MEK-ERK signaling may contribute to the drug-resistant nature of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393318     DOI: 10.1007/s10620-007-9798-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  43 in total

Review 1.  Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.

Authors:  Michiaki Kohno; Jacques Pouyssegur
Journal:  Prog Cell Cycle Res       Date:  2003

Review 2.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

3.  Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines.

Authors:  A F Soriano; B Helfrich; D C Chan; L E Heasley; P A Bunn; T C Chou
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation.

Authors:  Y Hu; M A Benedict; D Wu; N Inohara; G Núñez
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

6.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

7.  K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1.

Authors:  H Sheng; J Shao; R N Dubois
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

Review 8.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

9.  Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.

Authors:  B A Teicher; T T Korbut; K Menon; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells.

Authors:  T Kinoshita; T Yokota; K Arai; A Miyajima
Journal:  Oncogene       Date:  1995-06-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.